Ticlopidine increases nitric oxide generation in heart-transplant recipients: A possible novel property of ticlopidine

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 2, 1998, Pages 225-230

  De Lorgeril, Michel ^d   Bordet, Jean Claude ^a   Salen, Patricia ^e   Durbin, Santa ^a   Defreyn, Ghislain ^c   Delaye, Jacques ^b   Boissonnat, Pascale ^b  

^a UNIVERSITÉ LYON 1   (France)

^b LOUIS PRADEL HOSPITAL   (France)

^c SANOFI   (France)

^d HÔPITAL NORD   (France)

^e NONE

Author keywords

Nitric oxide; Platelets; Prostacyclin; Thromboxane; Ticlopidine; Transplantation

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; ADENOSINE DIPHOSPHATE; AZATHIOPRINE; CYCLOSPORIN; ICOSANOID; NITRIC OXIDE; PREDNISOLONE; PROSTACYCLIN; THROMBOXANE B2; TICLOPIDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; URINARY EXCRETION;

ANALYSIS OF VARIANCE; BLOOD PLATELETS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; NITRIC OXIDE; PLATELET AGGREGATION INHIBITORS; THROMBOXANES; TICLOPIDINE;

EID: 0031828076     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199808000-00009     Document Type: Article

References (39)

1. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987;4(suppl 5):19-25.
2. Forrat R, Ferrera R, Boissonnat P, et al. High prevalence of thromboembolic complications in heart transplant recipients. Transplantation 1996;61:757-62.
3. de Lorgeril M, Dureau G, Boissonnat P, et al. Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. Arterioscler Thromb 1992;12:222-30.
4. de Lorgeril M, Dureau G, Boissonnat P, et al. Increased platelet aggregation after heart transplantation: influence of aspirin. J Heart Lung Transplant 1991;10:600-3.
5. de Lorgeril M, Richard MJ, Arnaud J, et al. Lipid peroxides and antioxidant defenses in the accelerated transplantation-associated coronary arteriosclerosis. Am Heart J 1993;125:974-80.
6. Bordet JC, de Lorgeril M, Durbin S, et al. Systemic but not renal production of prostacyclin is highly reduced in cyclosporin-treated heart transplant recipients. Am J Cardiol 1993;72:486-7.
7. de Lorgeril M. Boissonnat P, Mamelle N, et al. Platelet aggregation and HDL cholesterol are predictive of acute coronary events in heart transplant recipients. Circulation 1994;89:2590-4.
8. Knapp HR, Healy C, Lawson J, FitzGerald GA. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res 1998;50:377-86.
9. Savi P, Herbert JM. ADP receptors on platelets and ADP-selective antiaggregating agents. Med Res Rev 1996;16:159-79.
10. Voss BL, Hamilton KK, Samara S, McKee PA. Cyclosporin suppression of endothelial prostacyclin generation: a possible mechanism for nephrotoxicity. Transplantation 1988;45:793-6.
11. Hattori Y, Kasai K, Emoto T, Hiraiwa M, Shimoda S. The inhibitory effect of cyclosporin on prostacyclin production by cultured endothelial cells from porcine aorta. Transplant Proc 1989; 21:3461-3.
12. Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporin A enhances platelet aggregation. Kidney Int 1987;32:889-95.
13. Batt AM, Siest G, Magdalou J, Galteau MM. Enzyme induction by drugs and toxins. Clin Chim Acta 1992;209:109-21.
14. Fitzgerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular diseases. Circulation 1983;67:1174-7.
15. Moncada S, Higgs A. The L/-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
16. Lopez-Farré A, Riesco A, Digiuni E, et al. Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. Circulation 1996;94:83-7.
17. de Lorgeril M, Boissonnat P, Dureau G, Guidollet J, Renaud S. Evaluation of ticlopidine, a novel inhibitor of platelet aggregation, in heart transplant recipients. Transplantation 1993;55:1195-6.
18. Boissonnat P, de Lorgeril M, Perroux V, et al. A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients. Eur J Clin Pharmacol 1997;53:39-45.
19. 1α. the major metabolite of prostacyclin. Prostaglandins 1988;36:421-31.
20. Conrad KP, Joffe GM, Kruszyna H, et al. Identification of increased nitric biosynthesis during pregnancy in rats. FASEB J 1993;7:566-71.
21. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate: a two-year follow-up study. Hypertension 1995;25:848-53.
22. Vanrenterghem Y, Lerut T, Roels L, Gruwez J. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;4:999-1002.
23. Hoyt G, Collin G, Billingham M, Miller DC, Jamieson SW. Effects of antiplatelet regimens in combination with cyclosporine on heart allograft vessel disease. J Heart Transplant 1984;4:54-5.
24. Dalal KB, Ebbe S, Mazoyer E, Carpenter D, Yee T. Biochemical and functional abnormalities in hypercholesterolemic rabbit platelets. Lipids 1990;25:86-92.
25. + exchange block epinephrine- and ADP-induced stimulation of human platelet phospholipase C by blockade of arachidonic acid release at a prior step. J Biol Chem 1986;261:8660-6.
26. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
27. Bhagat K, Collier J, Vallance P. Vasodilatation to arachidonic acid in humans: an insight into endogenous prostanoids and effects of aspirin. Circulation 1995;92:2113-8.
28. Yang X, Chowdhury N, Cai B, et al. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994;94:714-21.
29. Lewis NP, Tsao PS, Rickenbacher PR, et al. Nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 1996;93:720-9.
30. Balligand JL, Godfraind T. Endothelium-derived relaxing factor and muscle-derived relaxing factor in rat aorta: action of cyclosporin A. J Cardiovasc Pharmacol 1991;17:5213-21.
31. Verbeke M, Van de Voorde J, de Ridder L, Lameire N. Functional analysis of vascular dysfunction in cyclosporin treated rats. Cardiovasc Res 1994;28:1152-6.
32. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 1994;93:2244-50.
33. O'Neil GS, Chester AH, Kushwaha S, Rose M, Tadjkarimi S, Yacoub MH. Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br Heart J 1991;66:212-6.
34. Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996;93:457-62.
35. Mills RM, Billett JM, Nichols WW. Endothelial dysfunction early after heart transplantation. Circulation 1992;86:1171-4.
36. Treasure CB, Vita JA, Ganz P, et al. Loss of the coronary microvascular response to acetylcholine in cardiac transplant patients. Circulation 1992;86:1156-64.
37. Drexler H, Fischell TA, Pinto FJ, et al. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. Circulation 1994;89:1615-23.
38. Smith CJ, Sun D, Hoegler C, et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996;78:58-64.
39. Koifman B, Wollman Y, Gobomolny N, et al. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. J Am Coll Cardiol 1995;26:1251-6.